Continuous Diaphragm Monitoring for mechanically ventilated patients

Información del proyecto

DiaMon

Identificador del acuerdo de subvención: 718938

DOI

10.3030/718938

Proyecto cerrado

Fecha de la firma de la CE 12 Febrero 2016

Fecha de inicio 1 Marzo 2016

Fecha de finalización 31 Agosto 2016

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

RESPINOR AS
Norway

Objetivo

Mechanical ventilation (MV) is one of the most common interventions implemented in the intensive care unit (ICU). MV is associated with a number of complications such as atrophy, muscle weakness, pneumonia, tracheal stenosis and baro/volutrauma. Complications increase in likelihood with duration of ventilation, and studies show that 15% of the patients that are extubated must be put back on mechanical ventilation for extended treatment. Timing and adjustment of MV is therefore critical to ensure safe recovery.
MV has enormous costs for healthcare systems with US$1,500 per patient per day. MV patients in ICUs account for 6% of all ventilated patients but consume 37% of ICU resources. With an estimation of 1.35 million MV patients in the EU for an average of 4-5 days, this represents the enormous expenditure of US$3.3 billion (€3.1 billion) annually.
Respinor has developed a novel, small and flexible ultrasound sensor (DiaMon) that provides precise, continuous information on diaphragm movement over prolonged periods of time without the need of direct manual operation or expertise monitoring. The information from DiaMon will enable ICUs staff to optimise the interaction between patients and the mechanical ventilator, reduce ventilation time, and significantly reduce extubation failures.
With DiaMon, Respinor targets ICUs to offer a cost-efficient and innovative diagnostic tool that will substantially improve an expensive and critical medical procedure that is common – and increasingly growing in demand - in the global hospital healthcare market.
The accomplishment of the project objectives (Phases 1 and 2) will bring major benefits to Respinor with a cumulated turnover of 103 million € in 2025 in the mechanical ventilation market. DiaMon will furthermore greatly improve quality of treatment for ventilation patients, substantially reduce costs in ICUs, and leverage competence in mechanical ventilation treatment.

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › medicina clínica › neumología
• ciencias médicas y de la salud › medicina clínica › medicina intensiva
• ciencias sociales › economía y empresa › gestión y empresas › modelo de negocio
• ingeniería y tecnología › ingeniería eléctrica, ingeniería electrónica, ingeniería de la información › ingeniería electrónica › sensores
• ciencias naturales › ciencias físicas › acústica › ultrasonido

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.3. - Treating and managing disease
  

Tema(s)

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Coordinador

RESPINOR AS

• Aportación neta de la UEn: € 50 000,00
• Dirección: GAUSTADALLEEN 21 ; 0349 OSLO ; Noruega
• Pyme Sí:
  Región
  Norge › Oslo og Viken › Oslo
• Región: Norge › Oslo og Viken › Oslo
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00